

## 1 **Impacts of the COVID-19 pandemic on future seasonal influenza epidemics**

2 Zandra C. Felix Garza<sup>1\*</sup>, Simon P. J. de Jong<sup>1\*</sup>, Joseph Gibson<sup>1\*</sup>, Alvin X. Han<sup>1</sup>, Sarah van  
3 Leeuwen<sup>1</sup>, Robert P. de Vries<sup>2</sup>, Geert-Jan Boons<sup>2,3,4,5</sup>, Marliek van Hoesel<sup>1</sup>, Karen de Haan<sup>1</sup>,  
4 Laura van Groenigen<sup>1</sup>, Hugo D. G. van Willigen<sup>1</sup>, Elke Wynberg<sup>1,6</sup>, Godelieve J. de Bree<sup>7</sup>,  
5 Amy Matser<sup>6</sup>, Lia van der Hoek<sup>1</sup>, Maria Prins<sup>6</sup>, Neeltje A. Kootstra<sup>8</sup>, Dirk Eggink<sup>1,9</sup>, Brooke  
6 E. Nichols<sup>1,10</sup>, Menno D. de Jong<sup>1†</sup> & Colin A. Russell<sup>1,10†</sup>

7 \* Contributed equally, † Contributed equally

8 <sup>1</sup> Department of Medical Microbiology & Infection Prevention, Amsterdam University  
9 Medical Center, University of Amsterdam, Amsterdam, The Netherlands

10 <sup>2</sup> Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical  
11 Sciences, Utrecht University, Utrecht, The Netherlands

12 <sup>3</sup> Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA

13 <sup>4</sup> Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands

14 <sup>5</sup> Department of Chemistry, University of Georgia, Athens, GA, USA

15 <sup>6</sup> GGD Amsterdam, Amsterdam, The Netherlands

16 <sup>7</sup> Department of Infectious Diseases, Amsterdam University Medical Center, University of  
17 Amsterdam, Amsterdam, The Netherlands

18 <sup>8</sup> Department of Experimental Immunology, Amsterdam University Medical Center,  
19 University of Amsterdam, Amsterdam, The Netherlands

20 <sup>9</sup> Centre for Infectious Disease Control, National Institute for Public Health and the  
21 Environment, Bilthoven, The Netherlands

22 <sup>10</sup> Department of Global Health, School of Public Health, Boston University, Boston, MA,  
23 USA

24 Correspondence to C.A.R. ([c.a.russell@amsterdamumc.nl](mailto:c.a.russell@amsterdamumc.nl))

## 25 **Summary**

26 **Seasonal influenza viruses typically cause annual epidemics worldwide infecting 5-15%**  
27 **of the human population<sup>1</sup>. However, during the first two years of the COVID-19**  
28 **pandemic, seasonal influenza virus circulation was unprecedentedly low with very few**  
29 **reported infections<sup>2</sup>. The lack of immune stimulation to influenza viruses during this**  
30 **time, combined with waning antibody titres to previous influenza virus infections, could**  
31 **lead to increased susceptibility to influenza in the coming seasons and to larger and**  
32 **more severe epidemics when infection prevention measures against COVID-19 are**  
33 **relaxed<sup>3,4</sup>. Here, based on serum samples from 165 adults collected longitudinally before**  
34 **and during the pandemic, we show that the waning of antibody titres against seasonal**  
35 **influenza viruses during the first two years of the pandemic is likely to be negligible.**  
36 **Using historical influenza virus epidemiological data from 2003-2019, we also show that**  
37 **low country-level prevalence of each influenza subtype over one or more years has only**  
38 **small impacts on subsequent epidemic size. These results suggest that the risks posed by**  
39 **seasonal influenza viruses remained largely unchanged during the first two years of the**  
40 **COVID-19 pandemic and that the sizes of future seasonal influenza virus epidemics will**  
41 **likely be similar to those observed before the pandemic.**


## 42 Main text

43 The incidence of seasonal influenza has been unusually low since the start of the COVID-19  
44 pandemic in early 2020<sup>5,6</sup>, with cases reported to WHO remaining >80% below historical  
45 averages as of January 2022<sup>2,7</sup>. This dramatic reduction is likely due to non-pharmaceutical  
46 interventions aimed at reducing transmission and spread of SARS-CoV-2<sup>8,9</sup>, which are also  
47 effective in limiting exposure to seasonal influenza viruses. The global lull in influenza virus  
48 circulation during the past two years and consequent lack of immune stimulation has led to  
49 widespread concerns of increased susceptibility to seasonal influenza viruses in the  
50 population due to waning immunity, potentially resulting in larger and more severe epidemics  
51 in upcoming seasons<sup>9-11</sup>. Previous studies of antibody titres to seasonal influenza viruses  
52 prior to the COVID-19 pandemic showed that antibody titres against influenza A viruses  
53 typically wane to half peak levels 3.5-10 years after infection<sup>12-14</sup>. However, evidence is  
54 lacking on how antibody immunity against seasonal influenza viruses has changed during the  
55 near-absence of seasonal influenza in the COVID-19 pandemic and the impact this could  
56 have on future influenza epidemic size.

57 To investigate how the lack of influenza virus circulation since the start of the COVID-19  
58 pandemic has impacted antibody levels against seasonal influenza viruses, we measured  
59 antibody titres, based on haemagglutination inhibition (HI), to representative strains of  
60 seasonal A/H3N2, A/H1N1pdm09, B/Yamagata, and B/Victoria viruses in longitudinal serum  
61 samples collected every summer between 2017 and 2021 from 100 healthy male adults  
62 participating in the Amsterdam Cohort Studies on HIV infection and AIDS (ACS)<sup>15</sup> (Fig. 1a,  
63 Extended Data Fig. 1a, Extended Data Fig. 2, see Methods). Results from virological and  
64 syndromic surveillance in the Netherlands showed that influenza A/H3N2, A/H1N1pdm09  
65 and B/Yamagata viruses caused epidemics in the three influenza seasons prior to the onset of  
66 the COVID-19 pandemic (Fig. 1b) and that the epidemic activity during this period was  
67 consistent with patterns from 2010-2019 (Extended Data Fig. 3).

68 For all seasonal influenza virus types and subtypes, cohort mean HI titres increased after the  
69 2017/2018 influenza epidemic but returned to pre-2017/2018 levels by summer 2019 (Fig. 1a  
70 and Extended Data Fig. 2). From 2019 until 2021, mean HI titres remained largely unchanged  
71 for all influenza virus (sub)types, including during the COVID-19 pandemic period when  
72 there was negligible influenza virus circulation (Fig. 1a and Extended Data Fig. 2).

73 Differentiating the year-on-year individual HI titre distributions by titre rises that are  
74 indicative of recent influenza virus infection ( $\geq 4$ -fold increase,  $\geq 2$  log<sub>2</sub> units), showed that  
75 influenza A and B virus infections were most common in individuals with low antibody titres  
76 in the year prior to infection (Fig. 1c and Extended Data Fig. 2). Overall, the HI titre  
77 distributions of the cohort remained largely unchanged over the study period, including  
78 during the COVID-19 pandemic.



79

80 **Fig. 1. Waning antibody titres to seasonal influenza virus before and during the**  
 81 **COVID-19 pandemic.** **a**, Individual antibody titres against seasonal influenza viruses based  
 82 on haemagglutination inhibition (HI) assay from 2017-2021 among 70 healthy male adult  
 83 participants of the Amsterdam Cohort Studies on HIV infection and AIDS (ACS) cohort for  
 84 each influenza virus (sub)type (see Methods). Mean antibody titres changes across all  
 85 individuals are drawn in bold lines with error bars indicating the mean standard error ( $n=70$ ).  
 86 **b**, Seasonal influenza virus epidemic activity 2017-2021 in the Netherlands based on  
 87 virological and syndromic surveillance data. **c**, HI titre distributions in the ACS cohort  
 88 following each winter epidemic period coloured by influenza virus (sub)type. HI titre  
 89 distributions of individuals who experienced a  $\geq 2$   $\log_2$  units increase in HI titre ( $\geq 4$ -fold  
 90 increase in HI titre), indicating likely infection in the previous winter epidemic period,  
 91 are shown in grey bars. **d**, HI antibody titre waning rates by influenza virus (sub)type in adults  
 92 estimated from HI titres from 70 ACS and 65 RECoVERED participants. Error bars  
 93 correspond to the 50% and 95% credible interval from the Markov Chain Monte Carlo  
 94 algorithm used to explore the distribution of model parameters. Waning rate of -1.0  
 95 corresponds to one two-fold decrease in antibody titre in one year.

## 96 Antibody waning during pandemic

97 Using a mathematical model on the HI titres of ACS participants who were likely not  
 98 infected during the entire 2017-2021 period, *i.e.* no  $\geq 2$   $\log_2$  unit increases in HI titre, we  
 99 estimated that antibody titres against A/H3N2 viruses waned at -0.20  $\log_2$  units per year, 95%  
 100 credible interval (CI) (-0.24, -0.16); A/H1N1pdm09 viruses at -0.10, 95%CI (-0.12, -0.07);  
 101 B/Victoria viruses at -0.13, 95%CI (-0.16, -0.10); and B/Yamagata viruses at -0.14, 95%CI (-  
 102 0.17, -0.11) (Fig. 1d, Extended Data Fig. 2, and Extended Data Tables 1 and 2), in agreement

103 with waning rates previously reported for adults<sup>12,14</sup>. This indicates that substantial waning of  
104 immune protection against seasonal influenza viruses occurs at timescales that are  
105 substantially longer than the lull in seasonal influenza virus circulation during the first two  
106 years of the COVID-19 pandemic. We also calculated waning rates using HI titres from the  
107 same ACS individuals but only for the period after the start of the COVID-19 pandemic, *i.e.*  
108 2020-2021 (Fig. 1d, Extended Data Fig. 2, and Extended Data Tables 1 and 2). There was  
109 also no significant waning of HI titres against any of the viruses during this period.

110 To extend our observations beyond the ACS cohort, we also measured antibody titres to the  
111 same representative viruses in serum samples collected in mid-2020 and mid-2021 from a  
112 longitudinal cohort of adult COVID-19 patients who were confirmed not to be vaccinated  
113 against seasonal influenza viruses in 2020 (Extended Data Fig. 1b) (Viro-immunological,  
114 clinical and psychosocial correlates of disease severity and long-term outcomes of infection  
115 in SARS-CoV-2 – a prospective cohort study, referred to as RECoVERED<sup>16</sup>). In this cohort,  
116 we estimated waning rates towards A/H3N2, A/H1N1pdm09, B/Yamagata, and B/Victoria to  
117 be -0.15, 95%CI (-0.31, 0.01), -0.08, 95%CI (-0.19, 0.03), -0.08, 95%CI (-0.20, 0.04) and -  
118 0.10, 95%CI (-0.22, 0.02) log<sub>2</sub> units per year respectively, in good agreement with those  
119 derived from the ACS cohort (Fig. 1d, Extended Data Fig. 2, and Extended Data Table 1).  
120 Combining data from both cohorts for the 2020-2021 period, the estimated waning rate  
121 remained similar to previous estimates for A/H3N2, A/H1N1 and B/Yamagata, and  
122 negligible for B/Victoria (Extended Data Table 1). Measurement error was found to be  
123 consistent in both datasets at 0.38, 95%CI (0.36, 0.40) and 0.33, 95%CI (0.31, 0.36) log<sub>2</sub>  
124 units for the full ACS and RECoVERED cohorts respectively (Extended Data Table 1),  
125 corresponding to a one-sided probability of a 2-fold error of approximately 6 –10%. Taken  
126 together, these results suggest that there have only been negligible changes in antibody titres  
127 to seasonal influenza viruses among adults since the start of the COVID-19 pandemic.


128 The lack of HI antibody titre waning suggests that immunity to seasonal influenza viruses in  
129 adults is unlikely to have declined substantially during the first two years of the pandemic.  
130 However, previous work showed that waning in children might be different from adults and  
131 could have an impact on susceptibility to infection<sup>14</sup>. While not possible to investigate  
132 waning in children in our cohorts, historical lulls in circulation of particular influenza virus  
133 (sub)types and their impact on subsequent epidemics have the potential to offer insights into  
134 how changes in population immunity, or lack thereof, could impact seasonal influenza  
135 epidemics in the post-COVID-19 pandemic period.

### 136 **Past lulls in influenza virus circulation**

137 Prior to the COVID-19 pandemic, seasonal influenza virus circulation was highly  
138 heterogeneous with influenza epidemics typically being dominated by one or two of the four  
139 seasonal influenza viruses. This heterogeneity led to frequent periods of 1-3 years where

140 some of the seasonal influenza virus subtypes barely circulated in many countries. These  
 141 periods are potentially analogous to the first two years of the COVID-19 pandemic as the  
 142 near-absent circulation of some influenza virus (sub)types might render populations more  
 143 susceptible, hence leading to larger epidemics.

144 To investigate the impact of this heterogeneity, we computed the proportion of isolates  
 145 corresponding to each influenza (sub)type in 718 season-country pairs from 2002/2003 to  
 146 2019/2020, for 47 countries in temperate zones (Fig. 2a), based on influenza virus virological  
 147 surveillance data deposited in the WHO FluNet database<sup>7</sup>. Low or near-absent circulation of  
 148 an influenza virus (sub)type within a single season (*i.e.* a (sub)type accounting for <10% of  
 149 all influenza virus isolates in a country's season) occurred regularly during this period  
 150 accounting for 29%, 27%, and 38% of all country-season pairs for A/H3N2, A/H1N1pdm09  
 151 and influenza B viruses respectively (Fig. 2b).



152

153 **Fig. 2. The effects of previous years' influenza virus circulation on epidemic size and**  
 154 **composition.** **a**, Geographic distribution of countries included in the dataset for epidemic  
 155 composition by subtype, coloured by number of seasons. **b**, Proportion of viral isolates in  
 156 each epidemic by virus (sub)type, across all countries and seasons (0 indicates complete  
 157 absence, 1 indicates complete dominance). **c**, Geographic distribution of countries included in  
 158 the dataset for epidemic size by (sub)type. **d**, Relative epidemic sizes by virus (sub)type,  
 159 across all countries and seasons (the lower the number, the smaller the epidemic). **e**,

160 Epidemic dominance as a function of years since previous dominance, by (sub)type. Error  
161 bars correspond to 95% confidence interval from an exact two-tailed binomial test for  
162 proportions. **f**, Relative size of a (sub)type-specific epidemic as a function of number of years  
163 since previous dominance of that (sub)type in that country, coloured by season. Each point  
164 corresponds to a country. **g**, Relative size of a subtype's epidemic as a function of its size in  
165 the previous season and the sum of the two previous seasons' sizes. Each point corresponds  
166 to a country-season, coloured by the season. **h**, Posterior distributions of parameter estimates  
167 in a Bayesian hierarchical model for epidemic size, with one year since previous dominance  
168 (circles), previous epidemic size (diamonds), or sum of previous two epidemics' size  
169 (squares) as predictors, either with or without season effects. Estimates above the dotted line  
170 represent the season effects. Points, thick and thin lines correspond to the posterior mean,  
171 50% CI, and 95% CIs, respectively.

172 While virological surveillance data yield insights into the frequency of circulation of  
173 influenza viruses, it can be biased for estimating epidemic size due to year-on-year changes  
174 in virus sampling rates. To complement the virologically confirmed dataset used above, we  
175 estimated type and subtype-specific epidemic size based on influenza-like illness (ILI) data  
176 from the WHO FluID<sup>17</sup> database for 20 countries in Europe and the Middle East in the period  
177 from 2010 to 2020 (Fig. 2c). To compute epidemic sizes for each influenza (sub)type in each  
178 season, we multiplied a country's ILI burden by the proportion of isolates attributed to each  
179 type and subtype in each season. We then divided this number by the total ILI burden across  
180 all ten seasons and multiplied this number by the total number of seasons to calculate relative  
181 epidemic sizes. In these estimates, a relative size of one corresponds to the mean number of  
182 influenza virus infections in a single season for a given country, irrespective of type and  
183 subtype. Epidemic sizes lower than 0.1, indicating very small or absent epidemics, were  
184 observed for 28%, 23%, and 37% of country-seasons for A/H3N2, A/H1N1pdm09 and  
185 influenza B viruses, respectively (Fig. 2d).

186 To investigate the effect of periods of low influenza virus circulation on epidemic (sub)type  
187 composition, we calculated the probability of an influenza virus (sub)type's dominance as a  
188 function of years since previous dominance, where we defined dominance as a (sub)type  
189 accounting for >30% of a season's isolates (Fig. 2e). The probability of a (sub)type's  
190 dominance increased with greater number of years since previous dominance. However, this  
191 analysis also implies that there were periods of up to three years where an influenza (sub)type  
192 did not dominate in the past, indicating that periods of low to absent circulation of particular  
193 seasonal influenza viruses were also common before the COVID-19 pandemic. Mean  
194 epidemic sizes for each influenza virus (sub)type increased with time since dominance (Fig.  
195 2f). However, these increases were strongly related to probability of (sub)type dominance  
196 (Fig. 2e) and epidemic sizes varied substantially since last dominance, suggesting that the  
197 overall influence of time since dominance on epidemic size is relatively small.

198 Epidemic sizes of each (sub)type have a negative relationship with incidence of that specific  
199 (sub)type in the preceding year with large successive epidemics being rare (Fig. 2g left

200 column). However, this negative relationship largely disappears when taking into account the  
201 cumulative incidence of each (sub)type two years into the past (Fig. 2g, right column), with  
202 epidemics of high and low incidence both being likely to occur if preceded by years of low-  
203 to-mid incidence.

204 For each number of years since dominance, there is a striking degree of clustering of  
205 epidemic size across countries by season (Fig. 2f). For example, in the 2013/2014 and  
206 2016/2017 seasons, where A/H3N2 dominated in most countries two years prior, the relative  
207 incidence in 2016/2017 appeared consistently higher than in 2013/2014. Notably, in 10 of the  
208 20 countries included in our dataset, the first A/H3N2-dominant season (2011/2012) after the  
209 2009 A/H1N1pdm09 pandemic did not belong to the three largest A/H3N2 epidemics in the  
210 influenza seasons from 2010-2011 until 2019-2020, despite three years of near absent  
211 circulation.

## 212 **Season effects dominate epidemic size**

213 Given the degree of clustering of epidemic size by season, we hypothesized that the size of  
214 influenza virus (sub)type-specific epidemics could be explained by a combination of season-  
215 specific effects and effects related to the presence or absence of that virus (sub)type in the  
216 years preceding an epidemic. Season-specific effects, shared between countries in a single  
217 season, may include a variety of viral, host, environmental, or epidemiological variables,  
218 such as antigenic novelty, climate, heterosubtypic competition, or the flux of viral seeding<sup>18-</sup>  
219 <sup>21</sup>.

220 To investigate this hypothesis, we constructed a Bayesian hierarchical model that uses these  
221 effects as predictors of the (sub)type-specific size of seasonal influenza epidemics.  
222 Specifically, we considered models that individually include the number of years since  
223 previous dominance of that (sub)type, the size of that (sub)type's epidemic in the previous  
224 year, or the sum of that (sub)type's incidence in the previous two years as predictors. In these  
225 models, the season effects correspond to the predicted 'base size' of a (sub)type's epidemic,  
226 given that the previous dominance was in the previous year, given that there was no  
227 circulation in the previous year, or given that there was no circulation in the previous two  
228 years, respectively. These season effects are modulated by the effects of prior circulation to  
229 yield an epidemic's predicted size. Years since dominance, size in the previous year and the  
230 sum of previous two seasons' sizes individually had non-trivial effects on epidemic size (Fig.  
231 2h). However, between-season differences with regard to season effects were consistently of  
232 substantially greater magnitude than any of the predictors related to prior incidence across all  
233 model formulations, suggesting that season-specific factors unrelated to the absence or  
234 presence of viral circulation in the previous year(s) dominate epidemic size. Previous  
235 epidemic size appeared to have a moderate effect on epidemic size. This effect substantially  
236 decreased when looking at the sum of the two previous epidemic sizes (Fig. 2h).



237 Because epidemic sizes clustered strongly by season, which might obscure the effect of prior  
238 incidence in a model with season effects, we also considered models without season effects.  
239 Here, estimates on the impact of absence or presence of circulation in prior years on size  
240 were higher, but the differences between seasons with regard to season effects ('base sizes')  
241 remained far greater (Fig. 2h). For example, even when using parameters estimated from a  
242 model without season effects, the model predicts that the size of an A/H3N2 epidemic with  
243 the mean estimated season effect and previous dominance three years prior is smaller than an  
244 epidemic with the largest estimated season effect and A/H3N2 domination in the previous  
245 season. Models that included season effects exhibited much better predictive performance  
246 than models without season effects (Extended Data Fig. 4a). Additionally, models that  
247 included prior incidence of the opposite subtype had substantial effects of opposite sign,  
248 implying that the estimated effects of prior incidence might reflect a combination of prior  
249 incidence and effects of heterosubtypic competition (Extended Data Fig. 4b). These results  
250 suggest that inherent season-specific effects have more substantial effects on epidemic size  
251 than (sub)type-specific patterns of prior circulation.

252 Taken together, the lack of changes observed in the pattern of measured antibody titres  
253 against seasonal influenza viruses and nearly two decades of epidemiological data suggest  
254 that the near-absence of seasonal influenza virus circulation during the first two years of the  
255 COVID-19 pandemic is unlikely to result in substantially larger influenza epidemics in the  
256 years to come. The size of future influenza epidemics is likely to fall within the size  
257 distribution of epidemics in the years before the COVID-19 pandemic.

## 258 **References**

- 259 1. Petrova, V. N. & Russell, C. A. The evolution of seasonal influenza viruses. *Nat. Rev.*  
260 *Microbiol.* **16**, 47–60 (2017).
- 261 2. World Health Organization (WHO). Weekly Epidemiological Record. *Wkly.*  
262 *Epidemiol. Rec.* **96**, 241–264 (2021).
- 263 3. McCauley, J. *et al.* The importance of influenza vaccination during the COVID-19  
264 pandemic. *Influenza Other Respi. Viruses* (2021) doi:10.1111/irv.12917.
- 265 4. Wijesundara, D. K., Williams, C., Sun, W., Furuya, A. M. & Furuya, Y. Fear of  
266 Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still  
267 Exists. *Vaccines* **9**, 1198 (2021).
- 268 5. Olsen, S. J. *et al.* Changes in Influenza and Other Respiratory Virus Activity During  
269 the COVID-19 Pandemic - United States, 2020-2021. *MMWR. Morb. Mortal. Wkly.*  
270 *Rep.* **70**, 1013–1019 (2021).
- 271 6. Laurie, K. L. & Rockman, S. Which influenza viruses will emerge following the  
272 SARS-CoV-2 pandemic? *Influenza Other Respi. Viruses* **15**, 573–576 (2021).
- 273 7. World Health Organization (WHO). FluNet. Available at:  
274 <https://www.who.int/tools/flunet> (2021).
- 275 8. Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza

- 276 lineage extinction during the COVID-19 pandemic? *Nat. Rev. Microbiol.* 1–2 (2021)  
277 doi:10.1038/s41579-021-00642-4.
- 278 9. Qi, Y., Shaman, J. & Pei, S. Quantifying the Impact of COVID-19 Nonpharmaceutical  
279 Interventions on Influenza Transmission in the United States. *J. Infect. Dis.* **224**, 1500–  
280 1508 (2021).
- 281 10. Jones, N. Why easing COVID restrictions could prompt a fierce flu rebound. *Nature*  
282 **598**, 395–395 (2021).
- 283 11. Baker, R. E. *et al.* The impact of COVID-19 nonpharmaceutical interventions on the  
284 future dynamics of endemic infections. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 30547–  
285 30553 (2020).
- 286 12. Fonville, J. M. *et al.* Antibody landscapes after influenza virus infection or  
287 vaccination. *Science* **346**, 996–1000 (2014).
- 288 13. Lau, Y. C. *et al.* Variation by lineage in serum antibody responses to influenza B virus  
289 infections. *PLoS One* **15**, e0241693 (2020).
- 290 14. Ranjeva, S. *et al.* Age-specific differences in the dynamics of protective immunity to  
291 influenza. *Nat. Commun.* **10**, 1660 (2019).
- 292 15. Wolf, F. d. *et al.* Numbers of CD4+ Cells and the Levels of Core Antigens of and  
293 Antibodies to the Human Immunodeficiency Virus as Predictors of AIDS Among  
294 Seropositive Homosexual Men. *J. Infect. Dis.* **158**, 615–622 (1988).
- 295 16. Wynberg, E. *et al.* Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms  
296 During the First 12 Months After Illness Onset. *Clin. Infect. Dis.* (2021)  
297 doi:10.1093/cid/ciab759.
- 298 17. World Health Organization (WHO). FluID. [https://www.who.int/teams/global-](https://www.who.int/teams/global-influenza-program)  
299 [influenza-program](https://www.who.int/teams/global-influenza-program) (2021).
- 300 18. te Beest, D. E., van Boven, M., Hooiveld, M., van den Dool, C. & Wallinga, J. Driving  
301 Factors of Influenza Transmission in the Netherlands. *Am. J. Epidemiol.* **178**, 1469–  
302 1477 (2013).
- 303 19. Lam, E. K. S., Morris, D. H., Hurt, A. C., Barr, I. G. & Russell, C. A. The impact of  
304 climate and antigenic evolution on seasonal influenza virus epidemics in Australia.  
305 *Nat. Commun.* **11**, 2741 (2020).
- 306 20. Axelsen, J. B., Yaari, R., Grenfell, B. T. & Stone, L. Multiannual forecasting of  
307 seasonal influenza dynamics reveals climatic and evolutionary drivers. *Proc. Natl.*  
308 *Acad. Sci. U. S. A.* **111**, 9538–42 (2014).
- 309 21. Bedford, T. *et al.* Integrating influenza antigenic dynamics with molecular evolution.  
310 *Elife* **3**, (2014).

311

## 312 **Methods**

### 313 **Viruses**

314 Based on phylogenetics data, four seasonal influenza viruses, A/Netherlands/04189/2017  
315 (H3N2), A/Netherlands/10218/2018 (H1N1), B/Netherlands/04136/2017 (Yamagata), and

316 B/Netherlands/00302/2018 (Victoria), were selected as representatives of the four main  
317 types/subtypes of seasonal influenza viruses that circulated prior to the SARS-CoV-2  
318 pandemic. To select these strains, we downloaded high-quality (<5% ambiguous nucleotides,  
319 >95% full length) seasonal influenza virus haemagglutinin sequences (A/H3N2,  
320 N=1,396; A/H1N1pdm09, N=1,283; B/Yamagata, N=1,129; and B/Victoria, N=1,408)  
321 collected between 2016 and October 2021 from GISAID ([www.gisaid.org](http://www.gisaid.org)) and reconstructed  
322 maximum-likelihood phylogenetic trees for each influenza virus subtype using the general  
323 time reversible substitution model with IQ-TREE<sup>22</sup>. These trees were used to assess the  
324 representativeness of viruses from the Netherlands in the early portion of the study period and  
325 the selected viruses were all representative of viruses that caused epidemics in the  
326 Netherlands during the 2017/18 winter. All four viruses were propagated on Madin-Darby  
327 Canine Kidney (MDCK) cells in infection medium, which consisted of MEM-Eagle Medium  
328 /EBSS (Lonza, Geleen, The Netherlands) supplemented with MEM Non-Essential Amino  
329 Acids (Gibco, ThermoFischer Scientific, Amsterdam, The Netherlands), penicillin (100  
330 U/mL), streptomycin (100 g/mL), L-Glutamine (Lonza), HEPES (Lonza), and TPCKtrypsin  
331 (Sigma-Aldrich/Merck, Darmstadt, Germany). They were harvested after 72 hours of  
332 incubation at either 37°C (H3N2 and H1N1) or 33°C (Yamagata and Victoria) and checked  
333 by Sanger sequencing.

### 334 **Longitudinal serum samples**

335 A total of 630 serum samples from 165 healthy adults were collected in the Netherlands,  
336 longitudinally before and during the pandemic in two separate cohorts: 1. Amsterdam Cohort  
337 Studies on HIV infection and AIDS<sup>15</sup> (ACS) (100 participants and a total of 500 samples) and  
338 2. the Viro-immunological, clinical and psychosocial correlates of disease severity and long-  
339 term outcomes of infection in SARS-CoV-2 – a prospective cohort study<sup>16</sup> (RECoVERED)  
340 (65 participants and a total of 130 samples).

341 The initial aim of the Amsterdam Cohort Studies was to investigate the prevalence,  
342 incidence, and risk factors of HIV-1 infection. The study population consists of men who  
343 have sex with men and live mainly around the city of Amsterdam, the Netherlands. Enrolled  
344 men were both HIV-1 seronegative and HIV-1 seropositive. Participants from the ACS  
345 cohort included in our study were all HIV-1 seronegative men ranging from 22 to 70 years  
346 old at the time of first collected sample. Briefly, five samples were collected per participant,  
347 *i.e.* 1. mid-2017, 2. mid-2018, 3. mid-2019, 4. mid-2020, 5. mid-2021. Using only samples  
348 collected in the summer period potentially helps to overcome issues that could arise from the  
349 transient antibody boosts due to both infection and vaccination<sup>23</sup>. The Amsterdam Cohort  
350 Studies on HIV infection and AIDS was approved by the Medical Ethics Committee of the  
351 Amsterdam University Medical Centre of the University of Amsterdam, the Netherlands  
352 (MEC 07/182). Participation in ACS is voluntary and without incentive. Written informed  
353 consent of each participant was obtained at enrolment.

354 Data derived from the ACS samples was complemented by the data acquired from  
355 participants in the SARS-CoV-2 cohort RECoVERED. The aim of the RECoVERED cohort  
356 study is to describe the immunological, clinical and psychosocial sequelae of a SARS-CoV-2  
357 infection. Individuals aged 16 to 85 years with laboratory-confirmed SARS-CoV-2 infection  
358 were enrolled on May 2020 till the end of June 2021 in the municipal region of Amsterdam,  
359 the Netherlands. The RECoVERED study was approved by the medical ethical review board  
360 of the Amsterdam University Medical Centre (NL73759.018.20). All participants provided  
361 written informed consent. From RECoVERED, we selected a total of 65 individuals, both  
362 male and female adults ranging from 20 to 77 years old at the time of the first collected  
363 sample, all of which had a confirmed SARS-CoV-2 infection but were otherwise healthy and  
364 unvaccinated for influenza in 2020. For these 65 individuals, samples were collected in the  
365 summer period of 2020 and 2021 only (two total for each participant). Samples from the  
366 RECoVERED cohort add diversity in age and gender to the ACS samples set but lacked pre-  
367 pandemic samples.

### 368 **Haemagglutination Inhibition (HAI) assay**

369 All serum samples were receptor destroying enzyme (RDE)-treated, as described elsewhere<sup>24</sup>.  
370 Briefly, 100mL of serum samples from ACS individuals 1-30 were combined with 200mL of  
371 RDE; for serum samples from ACS individuals 31-100 and all 65 RECoVERED subjects,  
372 100mL of serum were combined with 300mL of RDE. This difference in protocol was per the  
373 instructions of the providers of the respective batches of RDE. Because of this protocol  
374 difference, the results of ACS participants 1-30 and 31-100 are shown separately. All samples  
375 were then incubated at 37°C for 18 to 20 hours. The RDE reaction was then halted by heating  
376 the treated samples at 56°C for 30 to 60 minutes.

377 The haemagglutination inhibition activity of all serum samples was tested in an  
378 haemagglutination inhibition assay as described elsewhere<sup>24,25</sup> using two replicates per  
379 sample for A/H1N1, B/Yamagata, and B/Victoria, and one single measurement for A/H3N2.  
380 Briefly, the haemagglutination titre of each of the four viruses was determined by doing a  
381 two-fold serial dilution of 50mL of each virus stock and adding 50mL of PBS and 25mL of  
382 1% turkey red blood cells (tRBCs) to each well, followed by one hour incubation at 4°C and  
383 the reading of the haemagglutination patterns. The virus stocks were then diluted to a  
384 concentration of 4 haemagglutination units (HAU). The diluted viruses were then incubated  
385 with 50mL of two-fold serially diluted serum, in a total volume of 75mL for 30 minutes at  
386 37°C. The initial dilution used for the serial dilution of the serum was 1:20 of the RDE  
387 treated serum. After the incubation step, 25mL of 1% turkey red blood cells were added to  
388 the serum-virus mix and incubated at 4°C for one hour. The haemagglutination inhibition  
389 patterns were then read out and used for the calculation of antibody titres. Due to the known  
390 inefficient agglutination of tRBCs by recent A/H3N2 viruses, we used glycan remodelled

391 turkey red blood cells expressing appropriate receptors for recent A/H3N2 viruses<sup>26</sup> for the  
392 implementation of the assay for the A/H3N2 virus stock.

### 393 **Data pre-processing**

394 Two approaches were used in selecting data from which to determine antibody waning rates.  
395 Firstly, we used samples from the RECoVERED cohort for the years 2020 and 2021, where  
396 all participants are confirmed to have not received an influenza vaccination between the two  
397 sample collections and no natural influenza infection can be safely assumed given the near  
398 absence of influenza in the Netherlands during this period. Second, we used the ACS data for  
399 the 5 years from 2017 to 2021. Individuals who experienced a 4 or greater fold increase in  
400 titre between consecutive visits for a particular strain had their data for the strain removed in  
401 order to remove the obscuring effects of vaccination and infection. The advantage of the  
402 former approach is the certainty regarding infection and vaccination status, the latter,  
403 however, allows a longer period of time over which to observe potentially subtle antibody  
404 waning dynamics.

### 405 **Antibody waning model**

406 True antibody titre  $\log_2$  HI,  $\tilde{T}^i$ , as opposed to that measured by haemagglutination inhibition  
407 assay,  $T^i$ , is a continuous variable which we assume, for every individual,  $i$ , decays with time,  
408  $t$ , as

$$409 \quad \tilde{T}^i = c^i - \alpha t \quad (1)$$

410 Where  $c^i$  are individual specific initial titres and  $\alpha$  is the shared waning rate.

411 If serum dilutions could be performed in arbitrarily small increments, we assume the point at  
412 which haemagglutination would be observed to cease,  $T_{obs}$ , to be distributed normally about  
413 the true value:

$$414 \quad T_{obs} \sim N(\tilde{T}, \epsilon) \quad (2)$$

415 where  $\epsilon$  shall be referred to as the “measurement error”. Instead, with discrete dilutions in  
416 increments of 1, the probability of measuring  $T \in \{0, 1, 2...8\}$  is the probability that  $T_{obs}$  falls  
417 between  $T$  and  $T - 1$ . Thus, the measurement probability is given by:

$$418 \quad P(T | \tilde{T}, \epsilon) = \begin{cases} \Phi(1, \tilde{T}, \epsilon) & T < 1 \\ \Phi(T, \tilde{T}, \epsilon) - \Phi(T_m - 1, \tilde{T}, \epsilon) & 1 \leq T < 8 \\ 1 - \Phi(8, \tilde{T}, \epsilon) & T \geq 8 \end{cases} \quad (3)$$

419 where  $\Phi(x, \mu, \sigma)$  is the cumulative distribution function of the normal distribution.

420 Our data for each individual,  $i$ , consists of a series of titre measurements,  $\mathbf{T}^{i,r} = (T_1^{i,r}, T_2^{i,r}, \dots,$   
 421  $T_n^{i,r})$ , at corresponding timepoints  $\mathbf{t}^i = (t_1^i, t_2^i, \dots, t_n^i)$ , where  $r \in \{1,2\}$  indicates replicate  
 422 measurements. To infer the probability of the unknown parameters  $\alpha$  and  $\epsilon$  given the data, it  
 423 is necessary to augment the data by introducing individual intercepts. For one replicate from  
 424 one individual, the likelihood of unknown parameters  $\alpha$ ,  $\epsilon$ , and  $c^i$  then becomes:

$$425 \quad p(\alpha, \epsilon, c^i | \mathbf{T}^{i,r}) \propto p(\mathbf{T}^{i,r} | \alpha, \epsilon, c^i) \Pi(\alpha, \epsilon, c^i) \quad (4)$$

$$426 \quad \propto p(\mathbf{T}^{i,r} | \tilde{\mathbf{T}}^i(\alpha, \epsilon, c^i)) \Pi(\alpha, \epsilon, c^i) \quad (5)$$

427 where  $\tilde{\mathbf{T}}^i(\alpha, \epsilon, c^i) = (\tilde{T}_1^{i,r}, \tilde{T}_2^{i,r}, \dots, \tilde{T}_n^{i,r})$  are the true values of titre, given the unknown  
 428 parameters and  $\Pi$  is the prior joint distribution of the parameters. The total log likelihood is  
 429 thus the sum over all individuals and replicates:

$$430 \quad L(\alpha, \epsilon, c | \mathbf{T}) \propto \sum_i \sum_r \log(p(\alpha, \epsilon, c^i | \mathbf{T}^{i,r})) \quad (6)$$

431 A Markov Chain Monte Carlo (MCMC) algorithm was used to explore the distribution of  
 432 model parameters (waning and measurement) and augmented data (individual intercepts). In  
 433 each iteration, model parameters were updated using a Metropolis-Hastings (MH) algorithm  
 434 and 10% of participants were randomly selected for updating of their augmented data, also  
 435 via MH. This model was run on 4 independent chains, each consisting of 20,000 iterations  
 436 discarding the first 5,000 as burn in. Non-informative priors were used and convergence was  
 437 assessed by inspection of the trace plots and Rhat from Stan v2.21.0. Analyses were  
 438 conducted using R v4.0.3, with code available in the Github repository.

### 439 Epidemic composition data

440 We downloaded records of virological surveillance data from the WHO FluNet<sup>7</sup> database for  
 441 all countries in the temperate Northern and Southern Hemisphere from 2002 until 2020, or a  
 442 shorter period for a limited subset of countries. For each country, we retained the longest  
 443 sequence of consecutive seasons in which at least 20 specimens were influenza-positive. In  
 444 each season, defined as the period from the period from week 40 until week 20 for the  
 445 Northern Hemisphere and the entire year for the Southern Hemisphere, we computed the  
 446 proportion of all positive tests that was attributable to each of A/H3N2, pandemic  
 447 A/H1N1pdm09 (from the 2009 pandemic onwards), and influenza B viruses. We did not  
 448 break down influenza B viruses by lineage because in many countries influenza B viruses  
 449 were not further characterized. In many seasons, only a proportion of all influenza A virus  
 450 positive tests were subtyped; in those cases, we approximated the total proportion of each  
 451 subtype by assuming that the subtype of the non-subtyped influenza A virus specimens were  
 452 distributed according to the relative proportions of subtyped influenza A viruses. This  
 453 resulted in a dataset of 679 season-country records over a period of 18 seasons, for 46

454 countries. We assigned a binary variable to each subtype/type in each season for dominance;  
455 we defined dominance as a subtype/type accounting for at least 30% of all isolates in a  
456 country in a season. Hence, in principle, all three subtypes/types considered can be  
457 simultaneously dominant in a single season. To avoid including effects of the COVID-19  
458 pandemic on influenza dynamics, we truncated the 2019-2020 season at the 15th of February  
459 2020, and to avoid including the effect of the 2009 A/H1N1pdm09 pandemic, we truncated  
460 the 2008-2009 influenza season at the 1st of April 2009.

## 461 **Epidemic size data**

462 To estimate epidemic sizes for each subtype/type, we extracted weekly records of influenza-  
463 like illness from the WHO FluID<sup>17</sup> database. We limited this dataset to countries for which  
464 ILI records were available for all seasons from 2010-2011 until 2019-2020, and for which  
465 virological surveillance data was available, as described above. Additionally, we required ILI  
466 curves to follow the expected shape of an influenza epidemic curve, *i.e.* peaking in winter and  
467 only sporadic isolation outside this period, and without periods of missing data. This yielded  
468 a set of 22 countries, each with 10 seasons worth of ILI data. We approximated the epidemic  
469 size of each subtype in each country per season by multiplying total ILI incidence in that  
470 country's season by the proportion of all isolates from that country in that season attributable  
471 to that subtype in the virological surveillance data. We computed the relative size of each  
472 subtype's epidemic in each country by computing the proportion of all ILI in the period from  
473 the 2010-2011 until 2019-2020 seasons that was attributable to that subtype and multiplying  
474 this number by the total number of seasons. Because this metric averages across all ten  
475 seasons, it gives an estimate of the size of an epidemic in a country, relative to all other  
476 seasons in that country, for each subtype. We accounted for the COVID-19 pandemic as  
477 described above.

## 478 **Statistical modelling**

479 To estimate the effect of presence or absence of influenza virus circulation in the previous  
480 year(s) on epidemic size, we performed Bayesian hierarchical linear regression. The first  
481 model has relative size as outcome and time since dominance as calculated using the  
482 virological surveillance data as predictor (N=188, 198, 180 for A/H3N2, A/H1N1pdm09 and  
483 B):

$$484 \quad y_i \sim N(a_{s[i]} + \beta x_i, \sigma_y) \quad (7)$$

485 where  $y_i$  is an epidemic's relative size for a certain (sub)type in country-season pair  $i$ ,  $a_{s[i]}$  is  
486 the season effect for that (sub)type corresponding to that season,  $\beta$  is the coefficient for  
487 number of years since dominance of the (sub)type, and  $s_y$  is the error standard deviation.  $x_i$   
488 represents the number of years since previous dominance of the (sub)type in country-season

489 pair  $i$  minus one, such that  $a_{s[i]}$  represents the predicted size if the previous dominance was in  
490 the previous year. Season effects are shared between countries in a single season.

491 We assumed that the season effects  $a_s$ , constrained to positive values, are distributed  
492 according to a common mean  $\mu_a$  and common standard deviation  $\sigma_a$ .

$$493 \quad a_s \sim N(\mu_a, \sigma_a) \quad (8)$$

494 We put weakly informative priors on the standard deviations, the mean season effect and the  
495 main effect.

$$496 \quad \beta \sim N(0,1) \quad (9)$$

$$497 \quad \mu_a \sim N(0.5,1) \quad (10)$$

$$498 \quad \sigma_a \sim \text{Half} - \text{Normal}(0,1) \quad (11)$$

$$499 \quad \sigma_y \sim \text{Half} - \text{Normal}(0,1) \quad (12)$$

500 We also ran a model with relative size as outcome and relative size in the previous year as the  
501 predictor (N=180 for each (sub)type) or the sum of the two previous years size (N=160 for  
502 each (sub)type). We use the same model specification and priors as for the size-years since  
503 dominance model, but we replace the predictor with the relative size in the previous season,  
504 or with the sum of relative size in the two previous seasons. For A/H3N2 and  
505 A/H1N1pdm09, we also ran these models with time since dominance, previous season  
506 epidemic size and sum of two previous seasons epidemics sizes of the other subtype as  
507 predictor (N=198, 188 for A/H3N2, A/H1N1pdm09 for time since dominance, N= 180, 160  
508 for each subtype for previous year, previous two years' sum, respectively). For all these  
509 above models, we also ran the same models without season effects, *i.e.* with a single value for  
510 the intercept, for which the prior is equal to the prior of the mean season effect in the model  
511 with season effects.

512 These models were each run for each subtype individually, for 3000 iterations, discarding the  
513 first 1000 as burn-in, with four independent chains. All models were fit using MCMC in Stan  
514 v2.21.0, with convergence assessed by inspection of Rhat ( $< 1.05$ ), effective sample size ( $>$   
515 200) and the trace plots. We compared models with and without season effects using leave-  
516 one-out cross-validation<sup>27</sup>.

## 517 **Statistics**

518 No statistical method was used to predetermine sample size. Data were not randomized nor  
519 analysed in a double-blinded manner. The haemagglutination inhibition activity of all serum



520 samples was tested in an haemagglutination inhibition assay using two replicates per sample  
521 for A/H1N1, B/Yamagata, and B/Victoria, and one single measurement for A/H3N2. Specific  
522 details regarding amount of data are indicated in the figure captions. For parameter estimates  
523 95% credible intervals were considered as the significant bounds and were calculated from  
524 the 2.5th and 97.5th percentiles of the MCMC traces. For Fig. 2e, error bars correspond to  
525 95% confidence interval from an exact two-tailed binomial test for proportions.

## 526 **Reporting summary**

527 Further information on research design is available in the Nature Research Reporting  
528 Summary linked to this paper.

## 529 **Data availability**

530 Accession codes for GISAID data used in this paper are provided as supplementary  
531 information files. Raw de-identified hemagglutination inhibition data and raw surveillance  
532 data downloaded from WHO FluNet and FluID can be found in the project GitHub repository  
533 (<https://github.com/AMC-LAEB/waning-immunity-to-flu>). Biological materials are available  
534 for study via the Amsterdam Cohort Studies on HIV infection and AIDS (ACS) and the Viro-  
535 immunological, clinical and psychosocial correlates of disease severity and long-term  
536 outcomes of infection in SARS-CoV-2 – a prospective cohort study (RECoVERED).

## 537 **Code availability**

538 Custom scripts used for data analysis and modelling are available at GitHub  
539 <https://github.com/AMC-LAEB/waning-immunity-to-flu>.

## 540 **Methods references**

- 541 22. Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic  
542 Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 543 23. Kucharski, A. J., Lessler, J., Cummings, D. A. T. & Riley, S. Timescales of influenza  
544 A/H3N2 antibody dynamics. *PLOS Biol.* **16**, e2004974 (2018).
- 545 24. *WHO Global Influenza Surveillance Network Manual for the laboratory diagnosis and*  
546 *virological surveillance of influenza.* (2011).
- 547 25. Aartse, A. *et al.* Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins  
548 Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans.  
549 *Vaccines* **9**, 717 (2021).
- 550 26. Broszeit, F. *et al.* Glycan remodeled erythrocytes facilitate antigenic characterization  
551 of recent A/H3N2 influenza viruses. *Nat. Commun.* **12**, 5449 (2021).
- 552 27. Vehtari, A., Gelman, A. & Gabry, J. Practical Bayesian model evaluation using leave-  
553 one-out cross-validation and WAIC. *Stat. Comput.* **27**, 1413–1432 (2017).

## 554 **Acknowledgements**

555 A.X.H., Z.C.F.G. and C.A.R. were supported by ERC NaviFlu (No. 818353). J.G. and C.A.R.  
556 were supported by NIH R01 (5R01AI132362-04). C.A.R. was also supported by an NWO  
557 Vici Award (09150182010027). R.P.dV. was supported by ERC starting grant 802780 and a  
558 Beijerinck Premium of the Royal Dutch Academy of Sciences. GJB was supported by the  
559 Netherlands Organization for Scientific Research (NWO TOPPUNT 718.015.003) and by an  
560 ERC advanced grant (101020769). The RECoVERED cohort is supported by NWO ZonMw  
561 (No. 10150062010002). The Amsterdam Cohort Studies on HIV infection and AIDS, a  
562 collaboration between the Public Health Service Amsterdam, the Amsterdam UMC of the  
563 University of Amsterdam, Medical Center Jan van Goyen and the HIV Focus Center of the  
564 DC-Clinics, are part of the Netherlands HIV Monitoring Foundation and financially  
565 supported by the Center for Infectious Disease Control of the Netherlands National Institute  
566 for Public Health and the Environment. We gratefully acknowledge the authors and  
567 originating and submitting laboratories (supplementary information) for the reference  
568 sequences retrieved from GISAID's EpiFlu Database used in this study. The authors thank  
569 Mr. Reinier van der Palen of the department of Chemical Biology and Drug Discovery,  
570 Utrecht University for practical assistance with turkey erythrocyte glycan remodeling.

## 571 **Author contributions**

572 Z.C.F.G., S.P.d.J., J.G., A.X.H., D.E., M.D.d.J, and C.A.R. designed the research; Z.C.F.G,  
573 S.v.L., M.v.H., K.d.H., and L.v.G executed the experimental work; Z.C.F.G. and S.v.L.  
574 generated the antibody titre data; E.W., G.J.d.B, H.D.G.v.W., A.M., L.v.d.H., M.P., N.K.,  
575 and M.D.d.J. collected the clinical samples; R.P.d.V. and G.J.B. made and provided the  
576 glycan remodelled turkey red blood cells; S.P.d.J. and J.G. implemented the modelling work  
577 and performed the data analysis; Z.C.F.G., S.P.d.J., J.G., A.X.H., B.E.N., and C.A.R. wrote  
578 the first draft of the paper. All authors contributed to the critical revision of the paper.

## 579 **Competing interests**

580 No competing interests.

581 **Correspondence and request for materials** should be addressed to C.A.R. –  
582 [c.a.russell@amsterdamumc.nl](mailto:c.a.russell@amsterdamumc.nl)